Trimethylammonium

Trimethylammonium

SCHEMBL874043

CN(C)C.CN(C)C.O=C(O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Trimethylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA9 Q16790 1/20 0.56
FFAR3 O14843 2/20 0.46
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
TSHR P16473 4/20 0.43
ALDH1A1 P00352 3/20 0.43
THPO P40225 2/20 0.38
NFKB1 P19838 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 1/20 0.38
APEX1 P27695 1/20 0.38
PMP22 Q01453 1/20 0.38
LMNA P02545 1/20 0.36
PHF8 Q9UPP1 2/20 0.33
KDM2A Q9Y2K7 2/20 0.33
TP53 P04637 1/20 0.33
ACHE P22303 1/20 0.33
KDM6B O15054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trimethylammonium SCHEMBL28443711 1.00 CA1 (0.56) CA1CA2CA9FFAR3LCK
Trimethylammonium SCHEMBL874044 1.00
Trimethylammonium SCHEMBL4398765 0.95 CA1 (0.50) CA1CA2CA9FFAR3LCK
Trimethylammonium SCHEMBL28125697 0.95
Trimethylammonium SCHEMBL28100436 0.95
Trimethylammonium SCHEMBL27780974 0.91 CA1 (0.46) CA1CA2CA9FFAR3LCK
Oxalic Acid SCHEMBL1579095 0.84 FFAR3 (0.42) CA1CA2CA9FFAR3LCK
Acetic Acid SCHEMBL153379 0.84
Acetic Acid SCHEMBL9621249 0.84 FFAR3 (0.70) CA1CA2CA9FFAR3LCK
Oxalic Acid SCHEMBL1579087 0.84 FFAR3 (0.42) CA1CA2CA9FFAR3LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118239501-A Method for synthesizing molecular sieve under near-neutral fluorine-free condition 浙江大学 2024-06-25 CN claimed
CN-109748808-B Preparation method of choline bicarbonate and carbonate 济南蓬勃生物技术有限公司 2021-12-24 CN claimed
CN-109503395-B Stable choline solution and preparation method thereof 济南蓬勃生物技术有限公司 2021-11-16 CN claimed
EP-3600246-A1 DRY POWDERS OF CANNABINOIDS AND METHODS FOR PREPARING DRY POWDERS Colorado Can LLC (US) 2020-02-05 EP claimed
CN-109748808-A A kind of preparation method of Choline Bicarbonate and carbonate 济南蓬勃生物技术有限公司 2019-05-14 CN claimed
CN-109503395-A A kind of stable choline solution and preparation method thereof 济南蓬勃生物技术有限公司 2019-03-22 CN claimed
WO-2018175637-A1 DRY POWDERS OF CANNABINOIDS AND METHODS FOR PREPARING DRY POWDERS COLORADO CAN LLC (US) 2018-09-27 WO claimed
US-20180271826-A1 DRY POWDERS OF CANNABINOIDS AND METHODS FOR PREPARING DRY POWDERS COLORADO CAN LLC (US) 2018-09-27 US claimed
CN-110234666-B Vinyl alcohol polymer containing side chain olefin and method for producing same 株式会社可乐丽 2025-06-03 CN disclosed
CN-119817576-A Low residue disinfectant wipe 阿萨达有限责任公司 2025-04-15 CN disclosed
CN-114728901-B Materials and methods for differential characterization of molecular conjugates and conjugates 詹森生物科技公司 2025-03-21 CN disclosed
CN-119553509-A Preparation method of high-elasticity wear-resistant fabric 王正文 2025-03-04 CN disclosed
CN-114990898-B High-elasticity wear-resistant fabric and preparation method thereof 上海宝鸟服饰有限公司 2025-01-24 CN disclosed
WO-2024137634-A1 KIT FOR PREPARING A VOLATILE PH GRADIENT MOBILE PHASE AND METHOD FOR DETECTING AN ANALYTE DIONEX CORPORATION (US) 2024-06-27 WO disclosed
US-20020165253-A1 Substituted quinolinecarboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-11-07 US disclosed
WO-2002070487-A1 SUBSTITUTED QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2002-09-12 WO disclosed
EP-1191948-A2 HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION NEORX CORPORATION (US) 2002-04-03 EP disclosed
WO-2000076556-A9 HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION NEORX CORP (US) 2001-11-08 WO disclosed
WO-2000076556-A2 HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION NEORX CORPORATION (US) 2000-12-21 WO disclosed
US-6053396-A APPLYING A POLYMER SELECTED FROM THE GROUP CONSISTING OF POLYMERS HAVING OXYGEN ATOMS IN THE MAIN CHAIN AND POLYMERS CAPABLE OF BEING THERMALLY DEPOLYMERIZED, TO THE METAL SURFACE OF METAL PART TO BE WELDED, WELDING THE METAL PARTS TOYO RIKEN CORPORATION (JP) 2000-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165253-A1 Substituted quinolinecarboxamides as antiviral agents ZC3HAV1, IRF3, EIF2AK2 CA1 2880/4885CA2 2319/4885CA9 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.